Trial reportPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2025
Dupilumab efficacy by disease severity in pediatric type 2 asthma.
Trial report in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma
One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Who cites it
1 citing paper in PubMed.
- Dupilumab efficacy by disease severity in pediatric type 2 asthma.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDupilumab demonstrated efficacy in children with asthma in phase 3 VOYAGE (NCT02948959) and open-label extension EXCURSION (NCT03560466) studies. This post hoc analysis assessed dupilumab's long-term efficacy by asthma severity at parent study baseline.
methodsChildren (6-11 years) with moderate-to-severe type 2 inflammatory asthma (PS baseline blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide ≥20 ppb) from placebo-controlled VOYAGE who enrolled in EXCURSION received dupilumab every 2 weeks for an additional 52 weeks. We assessed annualized severe exacerbation rates, change in pre-bronchodilator percent predicted forced expiratory volume in 1 second (FEV
resultsAmong 179 children (104 with moderate, 75 with severe asthma), dupilumab compared to placebo reduced unadjusted annualized severe exacerbation rates during VOYAGE in children with moderate (0.22 vs. 0.37) and severe (0.41 vs. 1.07) asthma, with sustained reductions in EXCURSION (moderate: 0.07 and 0.07; severe: 0.24 and 0.19). At VOYAGE Week 52, the change from the parent study baseline in pre-bronchodilator percent predicted FEV
conclusionLong-term dupilumab treatment reduced exacerbation rates and improved lung function and asthma control in children with type 2 asthma irrespective of disease severity, with numerically greater improvements in children with severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.